Comparative Pharmacology
Head-to-head clinical analysis: SAMSCA versus VAPRISOL IN 5 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAMSCA versus VAPRISOL IN 5 DEXTROSE IN PLASTIC CONTAINER.
SAMSCA vs VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective vasopressin V2 receptor antagonist; increases free water excretion, resulting in aquaresis and increased serum sodium concentration.
Selective vasopressin V2 receptor antagonist; inhibits water reabsorption in the renal collecting duct, leading to aquaresis.
15 mg orally once daily, increased to 30 mg once daily after 24 hours as needed, maximum 60 mg once daily.
IV infusion, initial dose 20 mg once, followed by 20 mg daily if serum sodium increases <5 mEq/L after 24 hours; max 40 mg daily.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy subjects; prolonged in hepatic impairment (up to 20 hours) and heart failure (up to 20 hours).
Terminal half-life: 10-15 hours; prolonged in renal impairment.
Primarily metabolized by CYP3A4; <1% excreted unchanged in urine. 80% of dose excreted in feces, 20% in urine as metabolites.
Renal: 95% as unchanged drug and metabolites; fecal: 5%.
Category C
Category C
Vasopressin Receptor Antagonist
Vasopressin Receptor Antagonist